BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

Immuno-oncology combinations showed mixed results at the first of two virtual annual meetings this year of the American Association for Cancer Research, with PD-L1 inhibitor Tecentriq atezolizumab reporting two negative readouts and uninspiring monotherapy data...
BioCentury | Apr 25, 2020
Product Development

AACR Primer: first virtual AACR meeting of year will include data from over 40 trials

Data from an allogeneic CAR T therapy, bispecific mAbs and new immuno-oncology combinations are some of the highlights expected at the first virtual meeting of the year for the American Association for Cancer Research. Due...
BioCentury | Apr 23, 2020
Finance

In Hong Kong’s largest biotech IPO of the year, antibody company Akeso raises $333M

Akeso raised HK$2.6 billion Thursday in the second and largest IPO this year on the Hong Kong exchange's biotech chapter, valuing the company at HK$12.3 billion. Akeso Inc. (HKEX:9926) sold 159.5 million shares at HK$16.18,...
Items per page:
1 - 3 of 3